TCR² Therapeutics Reports Second Quarter 2019 Financial Results and Provides Corporate Update
Last tcr2 therapeutics inc. earnings: 11/12 07:00 am
Check Earnings Report
Began dosing of TC-210 in the Phase 1/2 trial for patients with mesothelin-expressing solid tumors and an interim update anticipated in 4Q19/1Q20Leading clinical sites participating in the TC-210 trial include Sarah Cannon Research Institute, MD Anderson Cancer Center and the National Cancer InstituteIND filing for TC-110 in patients with CD19+ non-Hodgkin lymphoma or adult acute lymphoblastic leukemia anticipated in 2H19 CAMBRIDGE, Mass., Aug. 08, 2019 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company developing the next generation of novel T cell therapies for patients suffering from cancer, today announced financial results for the second quarter ended June 30, 2019 and provided a corporate update. "In the second quarter of 2019, we made significant progress with our two lead programs TC-210 and TC-110," said Garry Menzel, Ph.D., President and Chief Executive Officer of TCR2 Therapeutics. "We began patient dosing in a Phase 1/2 cl
[Read more]
| Impact snapshot | Event time: | TCRR | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last price | ||
| VWAP | ||
|
High:
|
Max up |
High:
|
|
Low:
|
Max down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event Day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance Since Event
Time and Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
SIGN UP TODAY
Opt-in for
TCRR alerts
TCRR alerts
from News Quantified
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TCRR alerts
High impacting TCR2 Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
TCRR
News
- TCR2 Therapeutics Inc. (<a href="https://www.marketbeat.com/stocks/NASDAQ/TCRR/price-target/">NASDAQ: TCRR</a>) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating.MarketBeat
- TCR² Therapeutics to Participate in Two Upcoming Conferences in JuneGlobeNewswire
- TCR2 Therapeutics Inc. (<a href="https://www.marketbeat.com/stocks/NASDAQ/TCRR/price-target/">NASDAQ: TCRR</a>) had its price target lowered by analysts at Wedbush from $57.00 to $45.00. They now have an "outperform" rating on the stock.MarketBeat
- TCR2 Therapeutics Inc. (<a href="https://www.marketbeat.com/stocks/NASDAQ/TCRR/price-target/">NASDAQ: TCRR</a>) is now covered by analysts at Mizuho. They set a "buy" rating and a $51.00 price target on the stock.MarketBeat
- TCR² Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate UpdateGlobeNewswire
- More
TCRR
SEC Filings
- 5/13/21 - Form 10-Q
- 5/13/21 - Form 8-K
- 4/30/21 - Form 8-K
- TCRR's page on the SEC website
- More